TY - JOUR
T1 - Amelioration of systemic autoimmune disease by the stimulation of apoptosis-promoting receptor Fas with anti-Fas mAb
AU - Nishimura-Morita, Yoshiko
AU - Nose, Masato
AU - Inoue, Tohru
AU - Yonehara, Shin
PY - 1997
Y1 - 1997
N2 - Fas antigen (Fas) is a cell surface receptor molecule that mediates apoptosis-inducing signals into activated and/or autoreactive peripheral T and B cells by stimulation with Fas ligand or agonistic anti-Fas mAb. The i.p. administration of the hamster anti-mouse Fas mAb RK-8, which induced apoptosis both in vivo and in vitro, did not kill adult mice, whereas those given another hamster anti-mouse Fas mAb Jo2 rapidly die of fulminant hepatitis with hemorrhage. Here, we report that MRL-gld/gld mice thoroughly recovered and/or were prevented from glomerulonephritis, arthritis, sialadenitis, vasculitis and lymphoadenopathy after receiving a single administration of the agonistic anti-mouse Fas mAb RK-8. The serum levels of autoantibodies were decreased after the administration. All the therapeutic effects of RK-8 persisted for > 6 months. These findings suggest that the systemic administration of agonistic anti-Fas mAb without fulminant hepatitis-inducing activity is a useful therapeutic strategy for treating systemic autoimmune disease.
AB - Fas antigen (Fas) is a cell surface receptor molecule that mediates apoptosis-inducing signals into activated and/or autoreactive peripheral T and B cells by stimulation with Fas ligand or agonistic anti-Fas mAb. The i.p. administration of the hamster anti-mouse Fas mAb RK-8, which induced apoptosis both in vivo and in vitro, did not kill adult mice, whereas those given another hamster anti-mouse Fas mAb Jo2 rapidly die of fulminant hepatitis with hemorrhage. Here, we report that MRL-gld/gld mice thoroughly recovered and/or were prevented from glomerulonephritis, arthritis, sialadenitis, vasculitis and lymphoadenopathy after receiving a single administration of the agonistic anti-mouse Fas mAb RK-8. The serum levels of autoantibodies were decreased after the administration. All the therapeutic effects of RK-8 persisted for > 6 months. These findings suggest that the systemic administration of agonistic anti-Fas mAb without fulminant hepatitis-inducing activity is a useful therapeutic strategy for treating systemic autoimmune disease.
KW - Apoptosis
KW - Arthritis
KW - Autoantibody
KW - Glomerulonephritis
KW - Lymphoadenopathy
KW - Sialadenitis
KW - Vasculitis
UR - http://www.scopus.com/inward/record.url?scp=0031438150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031438150&partnerID=8YFLogxK
U2 - 10.1093/intimm/9.12.1793
DO - 10.1093/intimm/9.12.1793
M3 - Article
C2 - 9466307
AN - SCOPUS:0031438150
VL - 9
SP - 1793
EP - 1799
JO - International Immunology
JF - International Immunology
SN - 0953-8178
IS - 12
ER -